Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Narrative) (Details)

v3.21.2
Significant Transactions (Narrative) (Details) - USD ($)
 3 Months Ended
Aug. 23, 2021
Sep. 30, 2021
Sep. 30, 2020
Stock purchase agreement, value of shares to be purchased   $ 2,500,000 $ 0
Purchase price allocated $ 7,500,000    
Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]      
Collaboration and license agreement, notice duration to terminate contract 30 days    
Purchase price allocated $ 7,500,000    
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]      
Collaboration and license agreement, royalty payment term 10 years    
Collaboration and license agreement, period to cure breach of contract 60 days    
Collaboration and license agreement, notice duration to terminate contract 90 days    
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member]      
Collaboration and license agreement, period to cure breach of contract 30 days    
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member]      
Milestone payments $ 15,000,000    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]      
Collaboration and license agreement, period to cure breach of contract 60 days    
Collaboration and license agreement, agreement term 5 years    
Collaboration and license agreement, notice duration to terminate contract 90 days    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member]      
Collaboration and license agreement, period to cure breach of contract 30 days    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Financing Requirement not Met [Member] | RubrYc Theraputics, Inc. [Member]      
Collaboration and license agreement, notice duration to terminate contract 30 days    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member]      
Milestone payments $ 15,000,000    
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Theraputics, Inc. [Member]      
Collaboration and license agreement, royalty payment term 10 years    
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]      
Stock purchase agreement, number of shares purchased 1,909,563    
Stock purchase agreement, value of shares purchased $ 5,000,000    
Stock purchase agreement, number of shares to be purchased 954,782    
Stock purchase agreement, value of shares to be purchased $ 2,500,000    
Preferential dividend rate percentage 8.00%    
Minimum required shares to be eligible for preferential dividend rate 1,500,000    
Proceeds from conversion of preferred stock to common stock $ 30,000,000    
Liability for the assumed acquisition   $ 2,500,000